Guangzhou Innogen Pharmaceutical Group Co Ltd

02591

Company Profile

  • Business description

    Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.

  • Contact

    No. 2 Tengfei Second Street
    Room 409, Building H Self-numbered Creative Building
    China-Singapore Guangzhou Knowledge City
    Huangpu District, Guangdong Province
    Guangzhou
    CHN

    https://www.innogenpharm.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    193

Stocks News & Analysis

stocks

Chart of the Week: Has gold reached bear market territory?

Investors are facing a shifting landscape.
stocks

ASX share benefiting from favourable industry trends

We anticipate further earnings growth.
stocks

Fair value upgrade for this ASX income player

Headwinds in listed energy stocks likely to have passed

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,885.6059.900.68%
CAC 407,816.9444.490.57%
DAX 4022,680.04117.160.52%
Dow JONES (US)46,341.511,125.372.49%
FTSE 10010,176.4548.490.48%
HKSE25,349.78561.642.27%
NASDAQ21,590.63795.993.83%
Nikkei 22553,600.762,537.044.97%
NZX 50 Index12,825.8786.24-0.67%
S&P 5006,528.52184.802.91%
S&P/ASX 2008,671.8053.100.62%
SSE Composite Index3,943.0151.151.31%

Market Movers